Neurology

Biomedical/pharma, Neurology

It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug has been celebrated by some as a breakthrough for Alzheimer’s patients, but others remain highly sceptical or even openly opposed to the FDA decision. What has caused the furor? And what will this approval mean for other biotech companies developing new drugs for neurodegenerative diseases (and for the VCs backing them)?
Augustine Therapeutics had a lot of announcements this month: the VIB spin-off just appointed Dr. Sylvain Celanire as CEO, strengthened its Board of Directors, set up a Scientific Advisory Board and received a €1.2 million VLAIO grant. All of the above is going to help the company to develop therapies for rare peripheral neuropathies and neurodegenerative disorders, starting with Charcot-Marie-Tooth disease. Backed by some major players in the Belgian life sciences ecosystem, this start-up is accelerating fast!
Leuven, Belgium, 23 March 2021 - Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of novel innovative therapies for rare peripheral neuropathies and neurodegenerative disorders, has received EUR 1.2 million in funding from the Flanders Agency for Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new medicines for peripheral neuropathies through innovative research by elucidating the mode of action of second-generation selective HDAC6 inhibitors developed by Augustine Therapeutics.
Leuven, Belgium, 19th March 2021 - Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare peripheral neuropathies and neurodegenerative diseases, announces the strengthening of the company with seasoned senior executive Dr. Erik Tambuyzer joining the Board of Directors. Tambuyzer brings valuable insights based on his long- lasting work in the biotech industry and with patients’ organizations for rare diseases. Academic researchers Dr. Ludo Van Den Bosch and Dr. Joris de Wit are joining the company’s Scientific Advisory Board. The reinforcement of Augustine Therapeutics’ boards is another important step in strengthening the company to further the development of new medicines treating multiple neurodegenerative diseases with high unmet need.
Leuven, Belgium, 18th March 2021 - Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare peripheral neuropathies and neurodegenerative diseases, announces the appointment of Dr. Sylvain Celanire, PhD as its Chief Executive Officer and the opening of drug discovery laboratories at the Leuven Bio-Incubator in Belgium.
V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain treatments. Biodol Therapeutics receives EUR 4.5 million to develop novel FLT3 inhibitors for the treatment of chronic and neuropathic pain, aiming to reach the clinic by early 2023.